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Abstract
We investigated and compared the toxicity profile, as well as possible neuroprotective effects, of some antiepileptic drugs in cultured
 .  . w xrat hippocampal neurons. We used two novel carbamazepine derivatives, S - y -10-acetoxy-10,11-dihydro-5H-dibenz b,f azepine-5-
 . w x  .carboxamide BIA 2-093 and 10,11-dihydro-10-hydroxyimino-5H-dibenz b,f azepine-5-carboxamide BIA 2-024 , and compared their
effects with the established compounds carbamazepine and oxcarbazepine. The assessment of neuronal injury was made by using the
 .  .3- 4,5-dimethylthiazol-2-yl -2,5-diphenyl MTT assay, as well as by analysing morphology and nuclear chromatin condensation
 .propidium iodide staining , after hippocampal neurons were exposed to the drugs for 24 h. The putative antiepileptic drugs, BIA 2-093 or
 .BIA 2-024 at 300 mM , only slightly decreased MTT reduction, whereas carbamazepine or oxcarbazepine were much more toxic at
lower concentrations. Treatment with the antiepileptic drugs caused nuclear chromatin condensation in some neurons, which is
characteristic of apoptosis, and increased the activity of caspase-3-like enzymes, mainly in neurons treated with carbamazepine and
 .oxcarbazepine. The toxic effect caused by carbamazepine was not mediated by N-methyl-D-aspartate NMDA or by a-amino-3-hydroxy-
 .5-methyl-isoxazole-4-propionate AMPA receptors. Moreover, the antiepileptic drugs failed to protect hippocampal neurons from the
toxicity caused by kainate, veratridine, or ischaemia-like conditions. q 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Epilepsy is one of the most common neurological dis-
eases, affecting at least 50 million people worldwide
 .Scheuer and Pedley, 1990 . The major antiepileptic drugs
in clinical use, i.e. phenytoin, carbamazepine, valproate
and phenobarbital, among others, were developed and
introduced between 1910 and 1970, and are referred to as
Afirst-generationB drugs. Several new anticonvulsant drugs,
such as vigabatrin, gabapentin, felbamate, lamotrigine and
oxcarbazepine, have been introduced into clinical practice
and are referred to as Asecond-generationB drugs. More
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recent anticonvulsants, which are in preclinical or clinical
development, can be considered as Athird-generationB drugs
 .Loscher, 1998a .¨
Carbamazepine has become the most frequently pre-
scribed first-line drug for the treatment of partial and
generalised tonic–clonic epileptic seizures Loiseau and
.Duche, 1995 . Moreover, carbamazepine has been used in´
the treatment of neuropathic pain and schizoaffective psy-
chosis. However, patients treated with carbamazepine may
develop toxic symptoms, such as drowsiness, dizziness,
ataxia and nausea. Other disadvantages of carbamazepine
 .are its enzyme-inducing properties Tateishi et al., 1999
 .and interaction with other drugs Yasui et al., 1997 , as
well as the increase in the incidence of congenital malfor-
 .mations Kaneko et al., 1999 . Although most of the toxic
symptoms of carbamazepine are in the central nervous
 .system CNS , the mechanisms by which this antiepileptic
0014-2999r00r$ - see front matter q 2000 Elsevier Science B.V. All rights reserved.
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drug causes toxicity are not completely clarified. Some
reports indicate that carbamazepine induces apoptosis in
cultured cerebellar granule cells Gao and Chuang, 1992;
.Nonaka et al., 1998 and decreases glutamine synthetase
 .activity Fraser et al., 1999 . Conversely, it was previously
shown that carbamazepine exerted protective effects against
focal ischaemia or anoxia Fern et al., 1993; Rataud et al.,
.1994; Minato et al., 1997 , or against toxicity induced by
glutamate or veratridine Mattson and Kater, 1989; Lakics
.et al., 1995; Mark et al., 1995 . In addition, carbamazepine
did not prevent status epilepticus-induced damage to neu-
 .rons in hippocampus and amygdala Pitkanen et al., 1996 .¨
Oxcarbazepine is an analogue of carbamazepine, with a
comparable anticonvulsant efficacy. It has the advantage of
a low incidence of allergic reactions and enzyme induc-
tion. In case of combination therapy with other antiepilep-
tic drugs, oxcarbazepine is usually better tolerated than
 .carbamazepine Elger and Bauer, 1998 . However, the
involvement of oxcarbazepine in neuronal toxicity has not
been investigated.
Since seizures are resistant to treatment with currently
available antiepileptic drugs in about 30% of patients with
epilepsy, more effective antiepileptic drugs are necessary.
In addition, because of the inadequacy of the currently
available antiepileptic drugs, in terms of safety, newly
developed drugs should be less toxic than existing drugs.
 .  . w xS - y -10-acetoxy-10,11-dihydro-5H-dibenz b,f aze-
 .pine-5-carboxamide BIA 2-093; Benes et al., 1999a and
w x10,11-dihydro-10-hydroxyimino-5H-dibenz b,f azepine-
 .5-carboxamide BIA 2-024; Benes et al., 1999b are repre-
sentative of new compounds, structurally related to carba-
mazepine and oxcarbazepine, with anticonvulsant activity,
as determined by maximal electroshock Benes et al.,
.1999a,b . These two compounds were specifically de-
signed to circumvent their further degradation to toxic
metabolites, such as epoxides, without losing anticonvul-
sant potency. For example, BIA 2-093 produces signifi-
cantly less motor and cognitive impairment than carba-
 .mazepine and oxcarbazepine Benes et al., 1999a . In the
present work, we used an in vitro system cultured hip-
.pocampal neurons , to investigate the toxic profile of BIA
2-093 and BIA 2-024, as well as their possible protective
effects against several neurotoxic insults, in comparison
with the antiepileptic drugs carbamazepine and oxcar-
bazepine.
2. Materials and methods
2.1. Cell culture
Hippocampal neurons were dissociated from hip-
pocampi of E18–E19 Wistar rat embryos, after treatment
 .with trypsin 1.0 mgrml; 15 min; 378C and deoxyribo-
 . 2q 2qnuclease I 0.15 mgrml in Ca - and Mg -free Hank’s
balanced salt solution 137 mM NaCl, 5.36 mM KCl, 0.44
mM KH PO , 0.34 mM Na HPO .2H O, 4.16 mM2 4 2 4 2
NaHCO , 5 mM glucose, supplemented with 0.001% phe-3
.nol red, 1 mM sodium pyruvate, 10 mM HEPES, pH 7.4 .
Hippocampal neurons were cultured in B27-supplemented
 .Neurobasal medium GIBCO , a serum-free medium com-
 .bination Brewer et al., 1993 , supplemented with gluta-
 .  . mate 25 mM , glutamine 0.5 mM and gentamicin 0.12
.mgrml . Cultures were kept at 378C in a humidified
incubator in 5% CO r95% air, for 7–8 days, the time2
required for maturation of hippocampal neurons.
For the assessment of neuronal injury with the 3- 4,5-
.dimethylthiazol-2-yl -2,5-diphenyltetrazolium bromide
 .MTT assay, or to measure the activity of caspase-3-like
enzymes, hippocampal neurons were plated on poly-D-
 .lysine-coated 0.1 mgrml multiwells at a density of 0.1=
106 or 0.2=106 cellsrcm2, respectively. For morphology
studies with Cresyl violet staining, or analysis of nuclear
condensationrfragmentation with propidium iodide stain-
ing, cells were plated at a density of 45=103 cellsrcm2
on poly-D-lysine-coated coverslips.
2.2. Exposure of hippocampal neurons to drugs
The hippocampal neurons were exposed to drugs for 24
h. The drugs were diluted in aliquots of 250 ml of condi-
tioned medium, taken from each well and placed in an
Eppendorf tube. Then, the aliquots were added back to the
corresponding well, and the medium was mixed gently to
preserve the integrity of neurons. The toxicity was as-
sessed by using either the MTT assay, by analysing neu-
ronal morphology, or by counting neurons with nuclear
condensation andror fragmentation. The activity of cas-
pase-3-like enzymes was also measured, as described in
the next.
2.3. MTT assay
Assessment of neuronal injury in cultured hippocampal
neurons was made by using the MTT assay. Briefly, Krebs
 .buffer with MTT 0.5 mgrml was added to the cultures
and incubated for 1 h at 378C in the incubation chamber.
MTT, when taken up by living cells, is converted from a
yellow to a water-insoluble blue-coloured product. The
precipitated dye was dissolved in 0.04 M HCl in iso-
 .propanol and colorimetrically absorbance at 570 nm
quantitated.
2.4. Morphology studies
After incubation of cultured hippocampal neurons with
the drugs, for 24 h, the culture medium was removed, the
cells were washed two times with phosphate-buffered saline
PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na HPO , 1.82 4
.mM KH PO , pH 7.4 , and fixed with 0.1% glutaralde-2 4
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hyde in PBS at 378C. After 30 min, the cells were washed
 .two times with PBS 10 min each time and then dehy-
drated in a gradient of ethanolrPBS 50%, 70%, 80%,
.95% and 100% ethanol and ethanolracetone 1:1, about 1
min per solution. After this procedure, the cells were
rehydrated in a gradient of ethanolrPBS 100%, 95%,
.80%, 70% and 50% ethanol and then washed two times
with PBS. The cells were stained with 0.5% Cresyl violet
for 5 min, washed several times with ultrapurified water,
and dried. Finally, the coverslips containing the cells were
 .mounted with Entellan Merck , and micrographs were
taken.
2.5. Propidium iodide staining
After incubation with the drugs, cells were fixed in 4%
paraformaldehyde and then stained with propidium iodide
 .1.3 mgrml in Krebs medium. Apoptotic neurons, with
condensedrfragmented nuclei, were counted by using a
fluorescence microscope and a triple filter Omega Optical
.XF63 . The neuronal counting was done by counting ap-
proximately 200 neurons in about 10 fields in each cover-
slip.
2.6. Caspase-3-like acti˝ity assay
After the exposure of hippocampal neurons to drugs for
24 h, the culture medium was aspirated, and the cultures
were washed two times with the following buffer: 50 mM
KCl, 50 mM PIPES, 10 mM EGTA and 2 mM MgCl , pH2
7.4, at 48C. The cells were again washed with the washing
buffer supplemented with 100 mM phenyl-methyl-sulfo-
nyl-fluoride, 1 mM dithiothreitol and 1 mgrml Chymo-
 .statin-Leupeptin-Antiparin-Pepstatin A CLAP . After this
procedure, cells were lysed at 48C with the previous
supplemented buffer, with 0.5% Triton, collected and
 .frozenrthawed at y808C three times . Protein concentra-
tion was determined, and 20 mg of protein was used for
 .each determination. The extract 20 mg was added to 40
 wml of reaction buffer 25 mM HEPES, 0.1% 3- 3-
. xcholamidopropyl dimethylammonio -1-propane-sulfonate
 .CHAPS , 10 mM dithiothreitol, 100 mM phenyl-methyl-
sulfonyl-fluoride, pH 7.5, which was supplemented with
100 mM Asp-Glu-Val-Asp-7-amino-4-trifluoromethyl
 .coumarin DEVD-AFC , a fluorogenic substrate for cas-
.pase-3 and related proteases and incubated for 30 min, at
378C.
 .  .  .Fig. 1. Neurotoxic effect caused by exposure of cultured hippocampal neurons to antiepileptic drugs for 24 h. A BIA 2-093 B BIA 2-024 C
 .  .  .Carbamazepine CBZ D Oxcarbazepine OXC . The concentrations of the antiepileptic drugs are indicated below the bars. The results are presented as
 .percentage of MTT reduction, compared to control conditions no drug , and represent the means"S.E.M. of at least three independent experiments
performed in triplicate. ) P-0.05, ) ) P-0.01 — Significantly different from control; Dunnett’s post-test.
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After incubation, the fluorescence was monitored exci-
.tation from 300 to 410 nm and emission 475 nm using a
Spex Fluoromax spectrofluorometer. The results are ex-
 .pressed as percentage of control no treatment , using
arbitrary fluorescence units, at an excitation wavelength of
390 nm.
2.7. Ischemia-like conditions experiments
Hippocampal neurons were exposed to Krebs medium
without glucose and supplemented with 2-deoxyglucose 5
.  .mM and sodium cyanide 2.5 mM , which inhibits cy-
tochrome c oxidase, for 10 min. After this period, neurons
were washed two times with Krebs medium with glucose
and incubated with Neurobasal medium in an incubation
chamber at 378C, for a 1- or 2-h recovery period. The
antiepileptic drugs tested were present during the is-
chaemic period and during the recovery period. After this
period, the metabolic activity was assessed by using the
MTT assay.
2.8. Chemicals
BIA 2-093, BIA 2-024, carbamazepine and oxcarbaze-
pine were obtained from BIAL, S. Mamede do Coronado,
 .  .Portugal. y -1- 4-Aminophenyl -4-methyl-7,8-methy-
lenedioxy-4,5-dihydro-3-methylcarbamoyl-2,3-benzodi-
 .azepine LY 303070 was a kind gift of Lilly Research
Laboratories, Indianapolis, IN, USA, and dizocilpine MK-
.801 was a kind gift of Merck Sharp and Dohme, NJ,
USA. Neurobasal medium, B27 supplement, gentamicin
 .and trypsin USP grade were purchased from GIBCO
BRL, Life Technologies, Scotland. Glutamate, DNase
 .DN-25 , veratridine, 2-deoxyglucose, sodium cyanide,
phenyl-methyl-sulfonyl-fluoride, CLAP and dithiothreitol
were purchased from Sigma, St. Louis, MO, USA. Kainate
was purchased from TOCRIS, Bristol, UK. Glutaraldehyde
and paraformaldehyde were obtained from Merck-
Schuchardt, Germany. Propidium iodide was purchased
from Molecular Probes, Leiden, The Netherlands. All other
reagents were from Sigma or from Merck-Schuchardt.
 .  .Fig. 2. Changes in the morphology of cultured hippocampal neurons treated with antiepileptic drugs for 24 h. A Control culture B 300 mM BIA 2-093
 .  .  .  .C 300 mM carbamazepine D 300 mM oxcarbazepine — 400= magnification; E Control F 300 mM oxcarbazepine — 1000= magnification. The
 .morphological aspect of hippocampal neurons treated with BIA 2-024 not shown or BIA 2-093 was similar. Micrographs show neurons stained with
 .  .0.5% Cresyl violet. The black bar in A–D represents 50 mm and in E–F represents 10 mm. The arrows show condensed andror fragmented nuclei.
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Carbamazepine, oxcarbazepine, BIA 2-093, BIA 2-024,
veratridine and LY 303070 stock solutions were prepared
 .in dimethyl sulfoxide DMSO .
2.9. Statistical analysis
The data are expressed as means"S.E.M. Statistical
significance was determined by using an analysis of vari-
 .ance ANOVA , followed by Dunnett’s or Bonferroni’s
post-tests, as indicated in the figure legends.
3. Results
3.1. Effects of antiepileptic drugs on the ˝iability of cul-
tured rat hippocampal neurons
We investigated the effect of 24 h exposure of cultured
hippocampal neurons to BIA 2-093, BIA 2-024, carba-
mazepine or oxcarbazepine. The presence of 300 mM BIA
2-093 for 24 h decreased the MTT reduction to 84.4"3.5%
 . P-0.05 , as compared to control no drug treatment;
. Fig. 1A . Lower concentrations of BIA 2-093 50 and 100
.mM did not cause toxicity. In the presence of BIA 2-024
 .300 mM the MTT reduction was 86.8"2.4% of the
 .control P)0.05; Fig. 1B . Treatment of hippocampal
neurons either with carbamazepine or with oxcarbazepine
caused a neurotoxic effect at lower concentrations, as
compared to BIA 2-093 or BIA 2-024. In the presence of
100 or 300 mM carbamazepine, the MTT reduction de-
 . creased to 82.8"5.3% P-0.05 or 75.4"2.3% P-
.  .0.01 of the control, respectively Fig. 1C . The toxic
effect caused by oxcarbazepine was even higher. Thus,
Fig. 3. Quantification of apoptotic hippocampal neurons exposed to
 .antiepileptic drugs for 24 h. The concentration in mM of BIA 2-093,
 .  .BIA 2-024, carbamazepine CBZ or oxcarbazepine OXC is indicated
below the corresponding bars. The results are presented as percentages of
apoptotic neurons, and represent the means"S.E.M. of at least three
independent experiments. ) P -0.05, ) ) P -0.01 — Significantly differ-
ent from control; Dunnett’s post-test.
Fig. 4. Activation of caspase-3-like enzymes in cultured hippocampal
 .neurons exposed to antiepileptic drugs. The concentration in mM of
 .  .BIA 2-024, BIA 2-093, oxcarbazepine OXC or carbamazepine CBZ is
indicated below the corresponding bars. The results are presented as
 .percentages of control no treatment , using arbitrary fluorescence units at
an excitation wavelength of 390 nm, and represent the means"S.E.M. of
at least three independent experiments. ) ) P -0.01 — Significantly
different from control; Dunnett’s post-test.
treatment of hippocampal neurons with 50, 100 or 300 mM
oxcarbazepine for 24 h decreased the reduction of MTT to
 .  .86.6"3.9% P-0.05 , 65.9"4.2% P-0.01 or 62.5
 ."3.2% of the control, respectively Fig. 1D . We also
exposed hippocampal neurons to the antiepileptic drugs for
 .shorter periods 1 h and measured metabolic activity 24 h
later, in order to assess possible delayed neurotoxic effects,
but the results indicated that the antiepileptic drugs were
 .not toxic under these conditions not shown .
Morphological studies showed neuronal deterioration,
mainly in hippocampal neurons exposed to high concentra-
 .tions of carbamazepine or oxcarbazepine Fig. 2 . How-
ever, some morphological changes were also observed in
neurons treated with high concentrations of either BIA
2-093 or BIA 2-024. In Fig. 2, hippocampal neurons
treated with BIA 2-024 are not shown since the morpho-
logical changes were similar to those of neurons treated
with BIA 2-093. Some neurons showed nuclear condensa-
tion, indicative of apoptosis, and other neurons appeared to
be disintegrated, suggesting necrotic-like cell death.
We also analysed nuclear condensationrfragmentation
in cultured hippocampal neurons exposed to the antiepilep-
tic drugs, by using propidium iodide, which stains nucleic
acids in cells pre-fixed with paraformaldehyde. In control
cultures, 13% of total neurons were apoptotic. In the
presence of 100 or 300 mM BIA 2-093, the proportion of
 .apoptotic neurons was 16"2% or 23"3% P-0.05 of
 .total neurons, respectively Fig. 3 . Similar results were
obtained with BIA 2-024: the proportion of apoptotic
neurons in cultures treated with 100 or 300 mM BIA 2-024
was 15"2% or 22"1% of total neurons, respectively.
The number of apoptotic neurons significantly increased in
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Fig. 5. Lack of protective effect of NMDA or AMPA receptor antagonists
 .on neuronal degeneration caused by carbamazepine CBZ; 300 mM .
 .NMDA receptor antagonist-MK-801 10 mM ; AMPA receptor antago-
 .nist-LY 303070 LY; 15 mM . The results represent the means"S.E.M.
of at least three independent experiments performed in triplicate, and are
presented as percentages of MTT reduction, compared to control condi-
 . ) ) )tions no drug treatment . P -0.05, P -0.01 — Significantly differ-
ent from control; Dunnett’s post-test.
the presence of either carbamazepine or oxcarbazepine.
Thus, when hippocampal neurons were exposed to 100 or
300 mM carbamazepine the proportion of apoptotic neu-
 .  .rons was 25"2% P-0.05 or 31"3% P-0.01 ,
respectively. In the case of oxcarbazepine 100 or 300
.mM the proportion of apoptotic neurons was 27"1%
 .  .P-0.01 or 39"3% P-0.01 of total neurons, re-
 .spectively Fig. 3 . These results indicate that the
antiepileptic drugs may cause apoptosis, at least at higher
concentrations.
3.2. Effects of antiepileptic drugs on the acti˝ity of cas-
pase-3-like enzymes
We measured the activity of caspase-3 and related
proteases in hippocampal neurons treated with antiepileptic
drugs by using a fluorogenic substrate for these enzymes.
The activity of caspase-3-like enzymes was higher in
oxcarbazepine-treated neurons than in neurons treated with
 .the other antiepileptic drugs Fig. 4 . The presence of BIA
 .  .Fig. 6. Lack of protective effect of BIA 2-093, BIA 2-024, carbamazepine CBZ or oxcarbazepine OXC on neuronal degeneration caused by exposure of
 .hippocampal neurons to kainate KA; 100 mM for 24 h. The concentrations of the antiepileptic drugs are indicated below the bars. The results represent
the means"S.E.M. of at least three independent experiments performed in triplicate, and are presented as percentages of MTT reduction under control
 . ) )conditions no drug treatment . P-0.01 — Significantly different from control; Dunnett’s post-test.
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 .  .2-024 300 mM or BIA 2-093 300 mM increased the
activity of caspase-3-like enzymes to only 120.7"3.8%
 .  .P)0.05 or 112.1"4.8% P)0.05 of the control,
respectively. However, oxcarbazepine and carbamazepine
caused a higher and significant increase, especially at high
concentrations. Thus, oxcarbazepine 50, 100 and 300
.mM increased the activity of caspase-3-like proteases to
 .115.4"7.9% P)0.05 , 145.8"9.8% and 283.9"5.6%
of the control, respectively. In the case of carbamazepine
 .300 mM , the activity of caspase-3-like enzymes in-
creased to 130.9"4.7% of the control, and no effect was
observed at 100 mM.
( )3.3. Effects of N-methyl-D-aspartate NMDA or a-amino-
( )3-hydroxy-5-methyl-isoxazole-4-propionate AMPA recep-
tor antagonists on the toxicity caused by carbamazepine
We also checked whether NMDA or AMPA receptors
are involved in the neurotoxic effect caused by carba-
mazepine. For this purpose, we treated hippocampal neu-
rons with a high concentration of carbamazepine 300
.  .mM in the presence of either MK-801 10 mM , a NMDA
 .receptor antagonist, or LY 303070 15 mM , an AMPA
receptor antagonist, and observed that these glutamate
receptor antagonists did not protect neurons from the
 .toxicity caused by carbamazepine Fig. 5 . Similar results
were obtained in neurons treated with oxcarbazepine not
.shown , suggesting that NMDA and AMPA receptors are
not involved in the toxicity caused by carbamazepine or
oxcarbazepine.
3.4. Kainate-induced neurotoxicity in cultured hippocam-
pal neurons: lack of protection by BIA 2-093, BIA 2-024,
carbamazepine or oxcarbazepine
Non-NMDA receptor activation contributes to the
epileptic phenomena and is also implicated in excitotoxic-
ity. Thus, we investigated whether BIA 2-093, BIA 2-024,
carbamazepine and oxcarbazepine act as neuroprotectors
against the neurotoxic effect caused by kainate. Treatment
of cultured hippocampal neurons with 100 mM kainate for
24 h decreased MTT reduction to 70.5"2.9% of the
 .control Fig. 6 . As previously shown, this neurotoxic
effect was mainly due to the activation of AMPA receptors
 .  .Fig. 7. Lack of protective effect of BIA 2-093, BIA 2-024, carbamazepine CBZ or oxcarbazepine OXC on neuronal degeneration caused by veratridine
 .Ver; 30 mM . The results represent the means"S.E.M. of at least three independent experiments performed in triplicate, and are presented as percentages
 . ) )of MTT reduction under control conditions no drug . P-0.01 — Significantly different from control; Dunnett’s post-test.
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 .Ambrosio et al., 2000 . The presence of BIA 2-093, BIA´
2-024, carbamazepine or oxcarbazepine, at concentrations
below those that did not cause any toxic effect, did not
 .protect neurons from kainate-induced toxicity Fig. 6 .
3.5. Veratridine-induced neurotoxicity: lack of protection
by BIA 2-093, BIA 2-024, carbamazepine or oxcar-
bazepine
 .The antiepileptic drugs BIA 2-093 Benes et al., 1999a ,
 .BIA 2-024 unpublished data , carbamazepine and oxcar-
bazepine McLean et al., 1994; Kuo et al., 1997; Benes et
.al., 1999a are known to block voltage-sensitive sodium
channels. We investigated whether these antiepileptic drugs
could protect hippocampal neurons against veratridine-in-
duced toxicity. Veratridine caused a concentration-depen-
dent neurotoxic effect. We observed that in hippocampal
neurons treated for 24 h with 10, 30 or 50 mM veratridine
 .the MTT reduction decreased to 85.6"1.8% P)0.05 ,
 .68.9"3.5% P-0.01 or 49.7"2.3% of the control,
respectively. In order to test the efficacy of the antiepilep-
tic drugs in protecting hippocampal neurons, we chose the
lowest concentration of veratridine that caused a signifi-
cant neurotoxic effect: 30 mM. The results obtained show
that the antiepileptic drugs, at concentrations below those
that caused toxicity, did not protect hippocampal neurons
 .from veratridine-induced toxicity Fig. 7 .
3.6. Chemical ischaemia-induced toxicity: lack of protec-
tion by BIA 2-093, BIA 2-024, carbamazepine or oxcar-
bazepine
Some reports indicate that antiepileptic drugs may be
neuroprotective under ischaemic conditions Rataud et al.,
.1994; Taylor, 1996 . We further investigated a possible
neuroprotective role of BIA 2-093, BIA 2-024, carba-
mazepine or oxcarbazepine, by testing their effects in
hippocampal neurons exposed to ischaemia-like condi-
tions. Exposure of hippocampal neurons to both 5 mM
2-deoxyglucose and 2.5 mM sodium cyanide, for 10 min,
decreased the MTT reduction to 49.0"3.7% of the con-
 .trol Fig. 8A . After washing and a further 1-h incubation
in Neurobasal medium, neurons partially recovered their
metabolic activity, since the MTT reduction increased to
qq69.3"4.1% of the control P-0.01, as compared to
.that after a 10-min exposure to deoxyglucose plus cyanide .
However, 2 h after exposure to ischaemia-like conditions,
an impairment of metabolic activity was observed, since
the MTT reduction was similar 54.2"3.3% of the con-
.trol to that observed when neurons were treated with
deoxyglucose and cyanide for 10 min, without a recovery
period. Moreover, when neurons were treated with either
deoxyglucose or cyanide, and left to recover for 2 h, the
 .MTT reduction was 83.6"3.6% P-0.05 or 86.8"
 .  .4.9% P)0.05 of the control, respectively Fig. 8A .
 .Fig. 8. A Evaluation of the metabolic activity of hippocampal neurons
exposed to ischaemia-like conditions. Hippocampal neurons were treated
 .  .with 5 mM 2-deoxyglucose DG andror 2.5 mM sodium cyanide CN
for 10 min. As indicated below bars, in some cases neurons were left to
recover for 1h or 2 h, respectively. The results represent the means"
S.E.M. of at least three independent experiments performed in triplicate,
and are presented as percentage of MTT reduction, compared to that
 . ) ) )under control conditions no drug . P -0.05, P -0.01 — Signifi-
cantly different from control; Dunnett’s post-test. qq P -0.01 — Signifi-
cantly different from chemical-ischaemia conditions; xx P -0.01 — Sig-
nificantly different from chemical-ischaemia conditions plus 1 h recovery
 .in Neurobasal medium; Bonferroni’s post-test. B Lack of protective
 .effect of BIA 2-093, BIA 2-024, carbamazepine CBZ or oxcarbazepine
 .OXC against ischaemia-like conditions in cultured hippocampal neu-
rons. In this particular case, ischaemic conditions were ischaemia-like
conditions plus 2 h recovery in Neurobasal medium, in the absence of
antiepileptic drugs. In non-control conditions the antiepileptic drugs 300
.mM were present during both ischaemic and recovery periods. The
results represent the means"S.E.M. of at least six independent experi-
ments performed in triplicate, and are presented as percentage of MTT
reduction, compared to that under ischaemic conditions.
We then investigated the effect of BIA 2-093, BIA
 .2-024, carbamazepine or oxcarbazepine at 300 mM on
the metabolic activity of hippocampal neurons exposed to
ischaemia-like conditions. The antiepileptic drugs were
present when hippocampal neurons were exposed for 10
( )A.F. Ambrosio et al.rEuropean Journal of Pharmacology 406 2000 191–201´ 199
min to both deoxyglucose and cyanide, as well as during
the 2-h recovery period. We chose a concentration of the
 .antiepileptic drugs 300 mM which was not toxic to
hippocampal neurons after a 2-h exposure. The results
show that the presence of the antiepileptic drugs did not
protect hippocampal neurons from the toxic effect caused
 .by ischaemia-like conditions Fig. 8B .
4. Discussion
4.1. Neurotoxic effect caused by antiepileptic drugs in
cultured hippocampal neurons
It is widely accepted that antiepileptic drugs may cause
CNS side effects. For example, antiepileptic drug therapy
can affect cognitive function in patients with epilepsy
 .Delcker et al., 1997; Meador, 1998 . Conversely, it has
been shown that some antiepileptic drugs have neuropro-
 .tective effects Rataud et al., 1994; Minato et al., 1997 . In
the present work, we used an in vitro preparation to
investigate the neurotoxicrneuroprotective profile of two
new anticonvulsants, BIA 2-093 and BIA 2-024, in com-
parison to the established compounds carbamazepine and
oxcarbazepine.
We found that BIA 2-093 and BIA 2-024 were less
toxic to hippocampal neurons than are the related com-
pounds, carbamazepine and oxcarbazepine, based on the
fact that carbamazepine and oxcarbazepine are more toxic
at lower concentrations. Indeed, at the highest concentra-
 .tion used 300 mM , BIA 2-024 did not cause a significant
toxic effect, as assessed either by MTT assay or by
propidium iodide staining. However, carbamazepine and
oxcarbazepine were toxic, although at concentrations above
those found in the CSF or plasma. For example, in hu-
mans, therapeutic serum levels of carbamazepine are 17–51
mM, and CSF levels may range from 17% to 31% of the
 .plasma concentration Rogawski and Porter, 1990 . More-
over, in rats receiving four times the ED dose of carba-50
mazepine against maximal electroshock seizure, the peak
brain extracellular fluid concentration is approximately 11
 .mM Dailey et al., 1997 . However, the concentrations
used in the present work were not different from the
concentrations reported previously Stefani et al., 1995;
Dailey et al., 1997; Nonaka et al., 1998; Benes et al.,
.1999a; Lingamaneni and Hemmings, 1999 . The toxic
effect observed at high concentrations may be relevant to
some of the adverse syndromes associated with over-
dosage.
It is important to mention that the antiepileptic drugs
studied are not metabolised by neuronal tissue in vitro
 .unpublished observations , but are rapidly metabolised in
vivo, giving origin to various metabolites, some of which
are also responsible for the effect of the drugs Rogawski
.and Porter, 1990; unpublished observations . Thus, it is
difficult to extrapolate these results to an in vivo situation.
However, these results may be useful to better understand
the mechanism of action of antiepileptic drugs, or even to
compare their neurotoxicrneuroprotective profile, since it
is important to find new antiepileptic drugs with fewer
CNS adverse effects.
Exposure of hippocampal neurons to high concentra-
tions of the antiepileptic drugs caused apoptosis, mainly in
the case of oxcarbazepine and carbamazepine, and the
apoptotic pathway may involve the activation of caspase-
3-like enzymes. It was previously shown that exposure of
cultured cerebellar granule cells to carbamazepine for 3
days induced apoptosis Gao and Chuang, 1992; Gao et al.,
.1995; Nonaka et al., 1998 . Some antiepileptic drugs,
including carbamazepine, were found to reduce glutamine
 .synthetase activity in mouse brain Fraser et al., 1999 , and
acute CNS side effects in healthy volunteers were also
 .reported Noachtar et al., 1998 . Oxcarbazepine is a new
antiepileptic drug that is almost clinically indistinguishable
from carbamazepine, but which has some improved prop-
erties, as for example in terms of liver enzyme-inducing
 .effects Elger and Bauer, 1998 . To our knowledge, there
are no reports in the literature concerning toxic effects of
this carbamazepine derivative in the CNS. Surprisingly, we
observed that oxcarbazepine was more toxic than carba-
mazepine. The toxic effect of oxcarbazepine was more
pronounced and was observed at lower concentrations.
It is well established that excessive activation of
ionotropic glutamate receptors causes neurodegeneration.
However, NMDA or AMPA receptors were not involved
in the neurotoxic effect caused by high concentrations of
carbamazepine, since the toxic effect was not prevented by
NMDA or AMPA receptor antagonists.
BIA 2-093 was found to be as potent as carbamazepine,
and more potent than oxcarbazepine, in preventing maxi-
mal electroshock-induced seizures, when the compounds
were given by gastric tube. Both BIA 2-093, carba-
mazepine and oxcarbazepine caused a dose-dependent mo-
tor impairment in rats. When the compounds were given
by intraperitoneal route, the protective index for BIA
2-093 was greater than the protective index for carba-
 .mazepine and oxcarbazepine Benes et al., 1999a . Thus,
these results, together with our findings, suggest that BIA
2-093 or BIA 2-024 may have some advantages as com-
pared to carbamazepine or oxcarbazepine.
4.2. Toxicity induced by kainate, ˝eratridine or
ischaemia-like conditions: lack of protection by BIA 2-093,
BIA 2-024, carbamazepine or oxcarbazepine
Glutamate is involved in the initiation of seizures and
their propagation, and some evidence indicates potential
roles for both NMDA and non-NMDA receptors Loscher,¨
.1998b . Moreover, kainic acid seizure models are widely
used to evaluate the efficacy of antiepileptic agents. Tak-
ing this into account, we investigated whether BIA 2-093,
BIA 2-024, carbamazepine or oxcarbazepine, at concentra-
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tions that did not cause toxicity, could have a neuroprotec-
tive effect on kainate-induced toxicity in hippocampal
neurons, which is essentially mediated by the activation of
 .AMPA receptors Ambrosio et al., 2000 . The results show´
that the antiepileptic drugs did not protect hippocampal
neurons from the toxicity caused by kainate.
Contrary to our results, it was previously reported that
carbamazepine afforded significant protection against glu-
tamate neurotoxicity in hippocampal cell cultures Mattson
.and Kater, 1989; Mark et al., 1995 , and reduced NMDA-
 .mediated brain injury McDonald and Johnston, 1990 . It
was suggested that the neuroprotective mechanism in-
w 2qxvolved stabilisation of Ca . These findings point toi
beneficial effects of antiepileptic drugs against ionotropic
glutamate receptor-mediated injury; however, in our sys-
tem, the antiepileptic drugs failed to protect hippocampal
neurons against toxicity mediated by glutamate receptors.
We found previously that carbamazepine inhibited
w 2qx  .kainate-induced Ca elevation Ambrosio et al., 1999 ,´i
but probably this effect was not enough to rescue neurons
from kainate-induced toxicity. We also found that
ionotropic glutamate receptors, both NMDA and non-
NMDA, were not affected by carbamazepine Ambrosio et´
.  .al., 1999 . Moreover, Grant et al. 1992 showed that the
inhibition caused by carbamazepine of NMDA-induced
responses appeared to be independent of the NMDA recog-
nition site. These findings suggest that blockade of
ionotropic glutamate receptors is not the mechanism by
which carbamazepine exerted protective effects in other
systems.
Since BIA 2-093, BIA 2-024, carbamazepine or oxcar-
bazepine inhibit voltage-sensitive sodium channels Mc-
Lean et al., 1994; Kuo et al., 1997; Benes et al., 1999a;
.unpublished observations , we investigated whether these
antiepileptic drugs could be neuroprotective against vera-
tridine-induced toxicity. The results showed that the
antiepileptic drugs did not protect hippocampal neurons
from veratridine-induced toxicity. Probably, the concentra-
tions of the antiepileptic drugs were not high enough to
inhibit the effect of veratridine. However, it was previ-
ously reported that some antiepileptic drugs, including
carbamazepine, protected rat cortical cultures against 100
 .mM veratridine-induced cell death Lakics et al., 1995 . In
addition, these authors suggested that mechanisms other
than sodium channel blockade may be involved in the
neuroprotection.
There is now substantial evidence from animal models
that sodium channel blockers prevent neuronal damage
 .caused by global and focal brain ischaemia Taylor, 1996 .
 .We used an ischaemic-like insult chemical ischaemia in
order to evaluate whether BIA 2-093, BIA 2-024, carba-
mazepine or oxcarbazepine has a neuroprotective effect in
hippocampal neurons. The effect of 2-deoxyglucose and
cyanide was synergistic, because exposure of hippocampal
neurons to either deoxyglucose or cyanide alone caused
only a small toxic effect. The presence of the antiepileptic
drugs, during and after the ischaemia-like insult, did not
protect hippocampal neurons. Conversely, in vivo studies
have demonstrated that some antiepileptic drugs, including
carbamazepine, reduce cerebral damage after focal is-
chaemia in rodents Rataud et al., 1994; Minato et al.,
.1997 , pointing to a therapeutic potential for voltage-de-
pendent sodium channel blockers. Such compounds may
act at sodium channels to prevent depolarisation, inhibiting
the release of neurotransmitters such as glutamate and thus
 .protecting the brain. Minato et al. 1997 also showed that
carbamazepine ameliorated the effects of brain infarction
and improved neurological deficits, but only above the
anticonvulsant dose. Contrary to this observation, it was
also shown that carbamazepine protected the rat optic
nerve against anoxic injury at concentrations well below
 .those used clinically to treat epilepsy Fern et al., 1993 .
Taken together, our results showed that the antiepileptic
drugs tested may be toxic to cultured hippocampal neu-
rons, at least at high concentrations, and that the toxic
effect is also observed as apoptosis. However, the new
putative antiepileptic drugs, BIA 2-093 and BIA 2-024,
were less toxic than carbamazepine or oxcarbazepine, with
oxcarbazepine being the most toxic. The activation of
NMDA or AMPA receptors did not contribute to the toxic
effect caused by carbamazepine. In addition, these
antiepileptic drugs failed to protect hippocampal neurons
against different toxic insults: kainate or veratridine expo-
sure, and ischaemia-like conditions. However, previous
findings for other systems, indicate that antiepileptic drugs,
under some conditions, can be neuroprotective.
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